VICTORIA, April 2, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES
LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF), a
provider of best-in-class therapeutic antibody discovery
capabilities for the global industry, today announced the
appointment of Yasmina Noubia Abdiche, Ph.D., as Chief Scientific
Officer, effective April 2020. Dr.
Abdiche will, among other responsibilities, lead the Company's
global research and development teams.
"We are excited to have Dr. Abdiche join the ImmunoPrecise
team," said Dr. Jennifer Bath, IPA's
President and CEO. "She has a distinguished background in
therapeutic antibody discovery and a strong track record of
advancing drugs to the clinic. With over 15 years of industry
experience Dr. Abdiche is a highly respected, strategic and
skilled thought leader with solid scientific and business
acumen."
Most recently, Dr. Abdiche was CSO at Carterra, where she helped
transition their LSA analytical antibody screening platform from
concept through prototype to global commercialization. Dr. Abdiche
previously served as a Research Fellow on the leadership team at
Rinat-Pfizer where she led a team of scientists providing core
support for biomolecular interaction analysis and played an active
role on the governing committee for Pfizer's Postdoctoral Program.
She is co-inventor of several therapeutic antibodies that entered
clinical trials including a current, market-approved drug,
Ajovy.
"I am thrilled to lead ImmunoPrecise's research and development
programs and accelerate their pre-clinical pipeline," stated Dr.
Yasmina Abdiche. "I am honored to work with the team of incredibly
talented and experienced scientists at IPA."
Dr. Abdiche graduated from Oxford
University with a Ph.D. in Biological Chemistry and a
Master's degree in Chemistry. She completed postdoctoral research
in Dr. David Myszka's laboratory at
the University of Utah in Salt Lake City, where she optimized biosensor
methods for characterizing small molecule interactions.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a
full-service, therapeutic antibody discovery Contract Research
Organization offering species agnostic, multi-format, characterized
and engineered, human monoclonal antibodies, on an abbreviated
timeframe, for its pharmaceutical clients. For further information,
visit www.immunoprecise.com or contact
solutions@immunoprecise.com.
Forward Looking Information
This news release
contains statements that, to the extent they are not recitations of
historical fact, may constitute "forward-looking statements" within
the meaning of applicable Canadian securities laws. The Company
uses words such as "may", "would", "could", "will", "likely",
"expect", "believe", "intend" and similar expressions to identify
forward-looking statements. Any such forward-looking statements are
based on assumptions and analyses made by ImmunoPrecise in light of
its experience and its perception of historical trends, current
conditions and expected future developments. However, whether
actual results and developments will conform to ImmunoPrecise's
expectations and predictions is subject to any number of risks,
assumptions and uncertainties. Many factors could cause
ImmunoPrecise's actual results to differ materially from those
expressed or implied by the forward-looking statements contained in
this news release. Such factors include, among other things, actual
revenues and earnings for IPA being lower than anticipated, and
those risks and uncertainties described in ImmunoPrecise's annual
management discussion and analysis for the last quarter ended
January 31, 2020 which can be
accessed at www.sedar.com. The "forward-looking
statements" contained herein speak only as of the date of this
press release and, unless required by applicable law, ImmunoPrecise
undertakes no obligation to publicly update or revise such
information, whether as a result of new information, future events
or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.